More on EVMN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.7 Score)

Upcoming Events

- Earnings (12/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Evommune (NY:EVMN)
Delayed: 5.10 -0.11 (2.11%)
Prev. Close $5.21  
Open$5.18 
52 Wk High$ 
52 Wk Low$ 
Day High$5.18 
Day Low$4.94 
P/E N/A  
EPS$ 
Volume280,830 


Oct 20, 2026 03:08 AM Morgan Stanley Assumes Evommune Inc (EVMN) at Overweight
Oct 15, 2026 04:29 PM Form 4 Evommune, Inc. For: Sep 30 Filed by: Pena Luis C.
Oct 12, 2026 02:20 AM UBS Starts Evommune Inc (EVMN) at Neutral
Oct 1, 2026 08:02 AM Form 8-K Evommune, Inc. For: Oct 01
Oct 1, 2026 08:01 AM Evommune reports Phase 2a data for EVO301 in atopic dermatitis
Oct 1, 2026 08:00 AM Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Sep 23, 2026 04:06 PM Form 8-K Evommune, Inc. For: Sep 23
Sep 23, 2026 04:05 PM Evommune to present EVO301 phase 2a data at EADV congress
Sep 23, 2026 04:05 PM Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Sep 18, 2026 07:03 AM Evommune (EVMN) Reiterated at Overweight by Cantor Fitzgerald on Tweaked OPEX Estimates
View All Articles

Entities mentioned with EVMN

View All Entities